[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf; Mäurer, Mathias; Stangel, Martin; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew Hao-Kuang; Czaplinski, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; ... (2021). [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]. Der Nervenarzt, 92(8), pp. 773-801. Springer 10.1007/s00115-021-01157-2

[img]
Preview
Text
Wiendl__2021__Multiple_Sklerose_Therapie_Kosten.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Chan, Andrew Hao-Kuang

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1433-0407

Publisher:

Springer

Language:

German

Submitter:

Chantal Kottler

Date Deposited:

25 Aug 2021 12:11

Last Modified:

25 Aug 2021 12:11

Publisher DOI:

10.1007/s00115-021-01157-2

PubMed ID:

34297142

Uncontrolled Keywords:

Autoimmune-mediated disease Early therapeutic intervention Guideline Immunotherapy Treatment recommendation

BORIS DOI:

10.48350/157961

URI:

https://boris.unibe.ch/id/eprint/157961

Actions (login required)

Edit item Edit item
Provide Feedback